Medtronic MDT Business Segments
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Cardiovascular | $13.98B+12.0% | $13.51B+10.1% | $13.09B+7.6% | $12.76B+6.4% | $12.48B+5.5% | |
| Diabetes | $3.11B+13.0% | $3B+11.8% | $2.9B+10.2% | $2.83B+10.7% | $2.76B+10.8% | |
| Medical Surgical | $8.81B+4.8% | $8.64B+2.9% | $8.54B+1.2% | $8.49B+1.0% | $8.41B-0.1% | |
| Neuroscience | $10.29B+4.5% | $10.16B+3.9% | $10.06B+4.0% | $9.95B+4.6% | $9.85B+4.7% | |
| Other Operating Segments | $135M-1.5% | $135.5M-14.2% | $136M-24.0% | $136.5M-31.8% | $137M-38.0% | |
| Reportable segment operating profit by Business | ||||||
| Cardiovascular | $3.67B+9.8% | $3.56B+49.0% | $3.49B+31.6% | $3.39B+13.6% | $3.34B+1.4% | |
| Medical Surgical | $2.13B+2.8% | $2.1B+40.3% | $2.11B+17.6% | $2.11B+1.9% | $2.07B-11.2% | |
| Neuroscience | $3.06B+1.0% | $3.04B+39.8% | $3.07B+27.4% | $3.05B+16.9% | $3.03B+6.3% | |
| Other segment items by Business | ||||||
| Cardiovascular | -$47M-14.6% | -$60M-76.5% | -$60M-122% | -$50M-85.2% | -$41M-46.4% | |
| Medical Surgical | $14M-22.2% | $13M-20.0% | $11M-24.1% | $14M+19.1% | $18M+100% | |
| Neuroscience | $36M+16.1% | $35M+32.1% | $35M+59.1% | $22M-34.3% | $31M+3.3% | |
| Cost of products sold, excluding amortization of intangible assets by Business | ||||||
| Cardiovascular | $4.69B+13.5% | $4.55B+14.1% | $4.35B+9.0% | $4.27B+9.0% | $4.14B+6.3% | |
| Medical Surgical | $3.48B+6.8% | $3.38B+6.5% | $3.3B+3.8% | $3.29B+4.3% | $3.26B+2.7% | |
| Neuroscience | $3.15B+8.8% | $3.1B+10.6% | $2.99B+7.8% | $2.96B+8.5% | $2.9B+4.9% | |
| Selling, general, and administrative expense by Business | ||||||
| Cardiovascular | $4.52B+12.4% | $4.34B+9.0% | $4.23B+7.0% | $4.1B+5.1% | $4.02B+3.1% | |
| Medical Surgical | $2.51B+4.7% | $2.45B+2.0% | $2.43B+1.3% | $2.41B+0.9% | $2.4B-0.1% | |
| Neuroscience | $3.42B+4.5% | $3.36B+3.2% | $3.34B+3.5% | $3.3B+3.6% | $3.28B+3.3% | |
| Currency translation and other by Business | ||||||
| Other Operating Segments | $0-100% | $250K— | $500K— | $750K— | $1M— | |
| Depreciation by Business | ||||||
| Cardiovascular | $253M+12.4% | $244M+12.6% | $234M+11.2% | $234M+14.6% | $225M+13.1% | |
| Medical Surgical | $225M+10.3% | $222M+11.3% | $211M+7.1% | $209M+7.5% | $204M+5.2% | |
| Neuroscience | $321M+14.2% | $308M+13.2% | $301M+14.9% | $293M+15.4% | $281M+11.5% | |
| Research and development expense by Business | ||||||
| Cardiovascular | $1.14B+11.4% | $1.12B+11.2% | $1.09B+7.7% | $1.04B+4.3% | $1.02B+2.9% | |
| Medical Surgical | $687M+3.2% | $693M+5.2% | $683M+4.1% | $673M+4.1% | $666M+3.1% | |
| Neuroscience | $616M+0.7% | $626M+1.1% | $625M+0.3% | $616M-0.8% | $612M-1.9% | |
| Net Sales by Geography | ||||||
| Ireland | $143M+22.2% | $134M+17.5% | $126M+11.5% | $120M+6.2% | $117M+4.5% | |
| Rest of world | $18.12B+11.5% | $17.57B+9.0% | $17.11B+6.7% | $16.77B+6.5% | $16.25B+3.6% | |
| United States | $18.1B+5.4% | $17.78B+4.8% | $17.52B+4.0% | $17.31B+3.5% | $17.17B+3.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Medtronic break its business down?
- Medtronic (MDT) reports net sales by business across 6 parts — Cardiovascular, Diabetes, Medical Surgical, Neuroscience and Other operating segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Medtronic's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Medtronic's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
